Translational Development Acquisition Corp.
NASDAQ:TDACShell Companies
-$0.01 today
- Market cap
- $267.99M
- Beta
- 0.01
- P/E (TTM)
- 29.8
- EPS (TTM)
- $0.36
Volume 0.47M
Average 0.10M
TDAC Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Translational Development Acquisition Corp.NASDAQ: TDAC
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses dips below year-ago levels
Q1 FY2026 other income / expenses of $1.61M fell 11.8% year over year, behind the +262.5% change in trailing-twelve-month other income / expenses. Sequentially, it fell 8.2% from the prior quarter.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -11.8% toward the trailing-twelve-month pace of +262.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 7.31M USD
- Year-over-year change
- +5729.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.31M | +5729.4% |
| FY2024 | 2024-12-31 | 125.35K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Income / Expenses vs competitors
How TDAC compares with its peers on the latest reported figures
- TDAC's LTM Mar 2026 other income / expenses of $7.09M is the 3rd highest of the 7 companies compared; the peer median is $7.03M.
- Its year-over-year change of +262.5% is the 3rd highest of 6, against a peer median of +131.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2022 | $16.7M | +556646666.7% | — | — | |
| LTM Mar 2026 | $9.05M | — | +42.6% | — | |
| LTM Mar 2026 | $7.09M | +262.5% | — | — | |
NTWONewbury Street II Acquisition Corp | LTM Mar 2026 | $7.07M | +131.3% | — | — |
| LTM Mar 2026 | $6.98M | +546.8% | -11.3% | — | |
MACIMelar Acquisition Corp. I | LTM Mar 2026 | $6.8M | +7.6% | — | — |
| LTM Mar 2026 | -$10.72M | -1003.5% | — | — | |
| Peer median (excluding TDAC) | $7.03M | +131.3% | +15.7% | — | |
Competitors are the stored peer set for TDAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 1.07M | 0 |
| Cost of Revenue | 0 | 0 | 320.87K | 0 |
| Gross Profit | 0 | 0 | 744.92K | 0 |
| Gross Margin | — | — | 69.9% | — |
| Research & Development | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 70.66K | 485.55K | 196.36K | 944.54K |
| Operating Expenses | 70.66K | 485.55K | 196.36K | 944.54K |
| Depreciation & Amortization | 70.66K | 0 | 0 | 0 |
| EBITDA | 0 | (485.55K) | (71.01K) | (944.54K) |
| EBITDA Margin | — | — | -6.7% | — |
| Operating Income | (70.66K) | (485.55K) | (196.36K) | (944.54K) |
| Operating Margin | — | — | -18.4% | — |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 508.56K | 0 |
| Other Income / Expenses | 0 | 0 | 125.35K | 7.31M |
| Income Before Tax | (70.66K) | (485.55K) | (71.01K) | 6.36M |
| Pre-Tax Margin | — | — | -6.7% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (70.66K) | (485.55K) | (71.01K) | 6.36M |
| Net Margin | — | — | -6.7% | — |
| EPS (Basic) | (0.02) | (0.12) | (0.02) | 0.37 |
| EPS (Diluted) | (0.02) | (0.12) | (0.02) | 0.37 |
| Weighted Avg Shares | 4.05M | 4.05M | 4.05M | 17.25M |
| Weighted Avg Shares (Diluted) | 4.05M | 4.05M | 4.05M | 17.25M |
Translational Development Acquisition Corp.
NASDAQ:TDAC
Intrinsic Alpha fair value
Locked
Current Price
$10.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.